Compare APPF & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APPF | PRAX |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1B | 9.6B |
| IPO Year | 2015 | 2020 |
| Metric | APPF | PRAX |
|---|---|---|
| Price | $176.94 | $297.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 15 |
| Target Price | $296.11 | ★ $572.13 |
| AVG Volume (30 Days) | ★ 374.7K | 325.2K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.88 | N/A |
| Revenue | ★ $950,822,000.00 | N/A |
| Revenue This Year | $19.69 | N/A |
| Revenue Next Year | $16.52 | $6,395.88 |
| P/E Ratio | $46.08 | ★ N/A |
| Revenue Growth | ★ 19.72 | N/A |
| 52 Week Low | $161.13 | $26.70 |
| 52 Week High | $325.90 | $354.87 |
| Indicator | APPF | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 41.02 | 38.07 |
| Support Level | $161.13 | $290.36 |
| Resistance Level | $191.16 | $322.32 |
| Average True Range (ATR) | 6.93 | 16.77 |
| MACD | 1.71 | -5.38 |
| Stochastic Oscillator | 47.22 | 13.28 |
AppFolio Inc provides cloud-based software solutions for the real estate industry. Its property management software offers property managers an end-to-end solution to their business needs. The group's products include cloud-based property management software (Appfolio Property Manager). Its solutions are AppFolio Property Manager Core, AppFolio Property Manager Plus, and AppFolio Property Manager Max. It also offers value-added services, such as screening, risk mitigation, and electronic payment services. Its markets are Single-Family, Multifamily, Student Housing, Affordable Housing, Community Associations, Commercial, and Investment Management. The business activity of the firm predominantly functions in the United States and it generates revenue in the form of subscription fees.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.